Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments

  • Technology appraisal guidance
  • TA927
  • Published: 
Download guidance (PDF)

Update information

Minor changes since publication

November 2023: We updated sections 2.1 and 2.2 upon publication of the summary of product characteristics for glofitamab.

ISBN: 978-1-4731-5429-2